CD20-targeted therapy: the next generation of antibodies

Semin Hematol. 2010 Apr;47(2):199-210. doi: 10.1053/j.seminhematol.2010.01.007.

Abstract

Targeting the CD20 antigen on B lymphocytes with the monoclonal antibody (MoAb) rituximab has greatly improved the outcome of patients with B-cell malignancies. Despite the success of rituximab, resistance occurs in about half of the patients, resulting in non-response to treatment or early relapse with the original disease. A better understanding of the mechanism of rituximab resistance has led to the development of novel, improved anti-CD20 antibodies. This review describes the development of CD20-targeted therapy from its historical background towards the next generation of anti-CD20 MoAbs and explains new strategies to overcome resistance.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antibody Specificity
  • Antibody-Dependent Cell Cytotoxicity
  • Antigens, CD20 / drug effects*
  • Antigens, CD20 / immunology
  • Apoptosis / drug effects
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / immunology
  • Complement Activation
  • Drug Delivery Systems
  • Drug Resistance
  • Humans
  • Recombinant Fusion Proteins / immunology
  • Recombinant Fusion Proteins / therapeutic use
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • PRO131921 monoclonal antibody
  • Recombinant Fusion Proteins
  • TRU-015 protein
  • Rituximab
  • ocrelizumab
  • veltuzumab
  • ofatumumab
  • ocaratuzumab
  • obinutuzumab